GCTK_OUT_1 [2025-04-01 11:05:59 -0400] 2316 Bytes | 668 tokens | Cum: 668 tkns (8.35% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and GlucoTrack (GCTK) hit my radar screen, up to 0.202 from a prev close of 0.1745 Do you think its got more juice or is it lacking potential? It's 11:05:58 AM on Tue Apr 01, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for GlucoTrack:

C1 - Mar-31-25 05:00PM - Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
C2 - Mar-19-25 08:01AM - Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
C3 - Feb-26-25 08:01AM - Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
C4 - Feb-05-25 11:52AM - Glucotrack Prices $3 Million Public Offering to Fund Expansion
C5 - Feb-04-25 01:44PM - Glucotrack hits trial success for direct blood measuring CGM
C6 - Feb-04-25 01:44PM 12:24PM - Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
C7 - Feb-04-25 01:44PM 08:01AM - Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
C8 - Jan-30-25 08:00AM - Glucotrack Announces Reverse Stock Split

Prior AI Reports for GCTK:
1. 2025-03-20 – Score: 8 – Target: 0.5000 – Highs: 0.5085 / 0.4900 / 0.30
glucotracks-financial-health-raises-investor-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on GlucoTrack (GCTK)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GCTK_OUT_3 [2025-04-01 11:06:04 -0400] 1107 Bytes | 324 tokens | Cum: 994 tkns (12.43% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights**
Date: Mar-31-25 05:00PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052830/0/en/Glucotrack-Reports-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html

March 31, 2025 17:00 ET| Source:GlucoTrack, Inc.GlucoTrack, Inc.

Transformational 2024: successfully advanced from preclinical to clinical stage company

Strengthened leadership team to drive growth and advance clinical development

Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies f

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GCTK_OUT_5 [2025-04-01 11:06:04 -0400] 988 Bytes | 284 tokens | Cum: 1358 tkns (16.98% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T21:37:59Z - Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | Taiwan News | ...
A2 - 2025-03-31T21:14:40Z - Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights...
A3 - 2025-03-31T21:08:58Z - Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights...
A4 - 2025-03-28T21:05:46Z - 12 Health Care Stocks Moving In Friday's After-Market Session - bluebird bio (NASDAQ:BLUE), Biodesix...
A5 - 2025-03-28T19:28:05Z - GCTK Stock Plummets to 52-Week Low of $0.20 Amid Market Turbulence By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GCTK_OUT_7 [2025-04-01 11:06:10 -0400] 1099 Bytes | 301 tokens | Cum: 1661 tkns (20.76% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | Taiwan News | Apr. 1, 2025 05:00**Date: 2025-03-31Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6073769Transformational 2024: successfully advanced from preclinical to clinical stage company

Strengthened leadership team to drive growth and advance clinical development

Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025

Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the four

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GCTK_OUT_9 [2025-04-01 11:06:18 -0400] 1099 Bytes | 237 tokens | Cum: 1997 tkns (24.96% of 8k)
==========================================================================

Showing A1 (chunk 2 of 17): th quarter and full year ended December 31, 2024.

"2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company. As we move into the next phase of growth, we have also strengthened our leadership team with key additions to our senior leadership, clinical and regulatory management team as well as our Medical Advisory Board," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "We are confident that our differentiated technology for blood glucose monitoring will change the lives of those living with diabetes and improve patient outcomes. This will be the first fully implantable CBGM technology with a multi-year monitoring system and real-time measuring capabilities, offering differentiated benefits of accuracy, convenience and independence for patients."

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GCTK_OUT_11 [2025-04-01 11:06:18 -0400] 1015 Bytes | 338 tokens | Cum: 2469 tkns (30.86% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-31T21:00:00Z - Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
B2 - 2025-01-29T14:00:00Z - Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
B3 - 2024-06-20T12:30:00Z - GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS
B4 - 2024-06-13T13:19:00Z - GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
B5 - 2024-06-10T14:50:00Z - GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE
B6 - 2024-06-05T12:30:00Z - GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GCTK_OUT_13 [2025-04-01 11:06:22 -0400] 758 Bytes | 200 tokens | Cum: 2671 tkns (33.39% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/31/3052830/0/en/Glucotrack-Reports-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.htmlGlucotrack, a medical technology company, reported strong progress in 2024, including advancing its continuous blood glucose monitoring technology from preclinical to clinical stage, strengthening its leadership team, and securing funding to support its growth plans.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GCTK_OUT_15 [2025-04-01 11:06:23 -0400] 1110 Bytes | 276 tokens | Cum: 2997 tkns (37.46% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Glucotrack, Inc. (the Company) issued a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnish...

S2 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The discussion in this section contains forward-looking statements. These statements relate to future events, our future operations or our future financial performance. We have attempt...

S4 - 2025-03-19 8-K Item 7.01 Regulation FD Disclosure

On March 19, 2025, Glucotrack, Inc., a Delaware corporation (the Company) issued a press release (the Press Release) announcing that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GCTK_OUT_17 [2025-04-01 11:06:30 -0400] 1098 Bytes | 231 tokens | Cum: 3230 tkns (40.38% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The discussion in this section contains forward-looking statements. These statements relate to future events, our future operations or our future financial performance. We have attempted to identify forward-looking statements by terminology such as anticipate, believe, can, continue, could, estimate, expect, intend, may, plan, potential, predict, should, would or will or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GCTK_OUT_19 [2025-04-01 11:06:41 -0400] 4236 Bytes | 1220 tokens | Cum: 4572 tkns (57.15% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------+
| Volume: 1,595,072 | Perf Month: -40.09% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 6.38M | Perf Quarter: -96.10% | Short Float: 2.79% | ROE: -1943.32% |
+--------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 1.02 | Index: - | Short Ratio: 0.04 | ROI: - |
+--------------------+-----------------------+------------------------+-------------------+
| RSI (14): 28.36 | Market Cap: 2.13M | Short Interest: 0.28M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.11 | Shs Outstand: 10.41M | Beta: 0.02 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA20: -34.76% | Shs Float: 10.17M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA50: -69.57% | Inst Own: 0.44% | Sales past 5Y: -25.00% | Earnings: - |
+--------------------+-----------------------+------------------------+-------------------+
| SMA200: -99.09% | Insider Own: 2.34% | Employees: - | |
+--------------------+-----------------------+------------------------+-------------------+
| Perf Week: -19.57% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Glucotrack, Inc. (GCTK) by Balo Andrew K (Unknown Title) on 2025-03-26
- Common Stock, par value $0.001 per share: 4490 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5087000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.1945
Average Volume: 7465271.64
30-Day High: 0.4135
30-Day Low: 0.1745

[Detailed Financials: Q3 2024]
- Total Assets: $826,000
- Total Liabilities: $4,848,000.0
- Total Equity: $-4,022,000.0
- Current Assets: $642,000
- Current Liabilities: $4,611,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.91

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $608,000
- Total Liabilities: $3,897,000.0
- Total Equity: $-3,289,000.0
- Current Assets: $442,000
- Current Liabilities: $3,660,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.82

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,942,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GCTK_OUT_21 [2025-04-01 11:06:43 -0400] 676 Bytes | 167 tokens | Cum: 4971 tkns (62.14% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GCTK_IN_23 [2025-04-01 11:06:44 -0400] 126 Bytes | 29 tokens | Cum: 5028 tkns (62.85% of 8k)
==========================================================================

====================================
[2025-04-01 11:06:44] # Analysis Completed
Elapsed Time: 45.68 seconds